Safety, Tolerability and Pharmacokinetics of MEDI8897, an Extended Half-life Single-dose Respiratory Syncytial Virus Prefusion F-targeting Monoclonal Antibody Administered as a Single Dose to Healthy Preterm Infants

BACKGROUND: MEDI8897 is a recombinant human monoclonal antibody being developed for prophylaxis of serious respiratory syncytial virus (RSV) disease in all infants. METHODS: In this phase 1b/2a dose-escalation study, healthy preterm infants with a gestational age of 32–35 weeks were randomized to re...

Descripción completa

Detalles Bibliográficos
Autores principales: Domachowske, Joseph B., Khan, Anis A., Esser, Mark T., Jensen, Kathryn, Takas, Therese, Villafana, Tonya, Dubovsky, Filip, Griffin, M. Pamela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Williams & Wilkins 2018
Materias:
Antimicrobial Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6133204/
https://www.ncbi.nlm.nih.gov/pubmed/29373476
http://dx.doi.org/10.1097/INF.0000000000001916

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6133204/
https://www.ncbi.nlm.nih.gov/pubmed/29373476
http://dx.doi.org/10.1097/INF.0000000000001916

Ejemplares similares